FreshPatents.com Logo
Enter keywords:  

Track companies' patents here: Public Companies RSS Feeds | RSS Feed Home Page
Popular terms

[SEARCH]

Rheumatoid Arthritis topics
Rheumatoid Arthritis
Osteoarthritis
Autoimmune
Multiple Sclerosis
Immune Disease
Autoimmune Disease
Antibodies
Astaxanthin
Hyaluronate
Hyaluronic Acid
Joint Pain
Hyaluronan
Immune Diseases
Autoimmune Diseases
Lung Cancer

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Rheumatoid Arthritis patents



      
           
This page is updated frequently with new Rheumatoid Arthritis-related patent applications. Subscribe to the Rheumatoid Arthritis RSS feed to automatically get the update: related Rheumatoid RSS feeds. RSS updates for this page: Rheumatoid Arthritis RSS RSS


Date/App# patent app List of recent Rheumatoid Arthritis-related patents
10/09/14
20140303902
 Methods, system, and medium for associating rheumatoid arthritis subjects with cardiovascular disease patent thumbnailMethods, system, and medium for associating rheumatoid arthritis subjects with cardiovascular disease
The present invention relates to a system and a medium for analyzing one or more analytes in rheumatoid arthritis subjects to determine whether the subject is at increased risk of diseases such as a cardiovascular disease, the subject's current cardiovascular disease burden, and the likelihood of cardiovascular disease progression in the subject. In addition, the present invention further provides methods for analyzing data to determine risk of cardiovascular disease, current cardiovascular disease burden, and the likelihood of cardiovascular disease progression in a rheumatoid arthritis subject..
10/09/14
20140303142
 Azaindoles as janus kinase inhibitors patent thumbnailAzaindoles as janus kinase inhibitors
The instant invention provides compounds of formula i which are jak inhibitors, and as such are useful for the treatment of jak-mediated diseases such as rheumatoid arthritis, asthma, copd and cancer.. .
10/09/14
20140302053
 Compositions for the treatment of rheumatoid arthritis and methods of using same patent thumbnailCompositions for the treatment of rheumatoid arthritis and methods of using same
The present invention provides compositions and methods of treating and improving the symptoms of rheumatoid arthritis using an antibody or antigen-binding fragment thereof that specifically binds human interleukin-6 receptor (hil-6r) with a dmard.. .
10/02/14
20140294897
 Potent lna oligonucleotides for the inhibition of hif-1a expression patent thumbnailPotent lna oligonucleotides for the inhibition of hif-1a expression
The present disclosure relates to an lna oligonucleotide consisting of a sequence selected from the group consisting of 5′-(tx)gxgxcsasasgscsastscscstxgxt-3′ and 5′-(gx)txtxascstsgscscststscstxtxa-3′, wherein capital letters designate a beta-d-oxy-lna nucleotide analogue, small letters designate a 2-deoxynucleotide, underline designates either a beta-d-oxy-lna nucleotide analogue or a 2-deoxynucleotide, subscript “s” designates a phosphorothioate link between neighbouring nucleotides/lna nucleotide analogues, and subscript “x” designates either a phosphorothioate link or a phosphorodiester link between neighbouring nucleotides/lna nucleotide analogues, and wherein the sequence is optionally extended by up to five 2-deoxynucleotide units. The lna oligonucleotides are useful for modulating the expression of hypoxia-inducible factor-1a (hif-1a), e.g.
10/02/14
20140294856
 Combination treatment comprising a hdac6 inhibitor and an akt inhibitor patent thumbnailCombination treatment comprising a hdac6 inhibitor and an akt inhibitor
The invention provides compositions comprising a histone deacetylase 6 (hdac6) inhibitor and an akt inhibitor, pharmaceutical compositions/formulations and kits of parts comprising the same; optionally further comprising one or more anti-cancer agents. The compositions of the invention provide for surprisingly efficacious killing of inter alia, cancer cells.
09/25/14
20140288011
 Genetic association patent thumbnailGenetic association
This invention is directed in part to methods, assays and/or kits for identifying an individual who has an autoimmune disease (such as rheumatoid arthritis), or who has an altered risk for having or developing the autoimmune disease. The methods in one aspect comprise determining the presence or absence of a nucleic acid variant within the somatostatin receptor type 2 (sstr2) gene in the individual's nucleic acids, wherein the presence of the nucleic acid variant is correlated with having the autoimmune disease or the altered risk.
09/18/14
20140277220
 Heated garment for medical applications patent thumbnailHeated garment for medical applications
A patient-treatment system and related method provide relief from, and treatment for, muscle spasticity disorders, willis-ekbom disease, contracture, sleep onset insomnia, sleep maintenance insomnia, rheumatoid arthritis, and other similar disorders by applying controlled heat, and optionally muscle monitoring/stimulation, to one or more parts of a patient's body.. .
09/18/14
20140275203
 Method for inhibiting differentiation of osteoclast and pharmaceutical composition comprising thereof patent thumbnailMethod for inhibiting differentiation of osteoclast and pharmaceutical composition comprising thereof
The present invention is for method of treating metabolic bone disease, new compounds and pharmaceutical compositions comprising the active ingredients having inhibition effects on osteoclast differentiation. The pharmaceutical composition comprising new compounds according to the present invention can be used as medicines for treating metabolic bone diseases such as bone metastatic cancer, solid cancer bone metastasis, musculoskeletal complication by solid cancer bone metastasis, hypercalcemia by malignant tumor, multiple myeloma, primary bone tumor, osteoporosis, rheumatoid arthritis, osteoarthritis, periodontal disease, inflammatory resorption of alveolar bone, inflammatory resorption of bone, and paget's disease..
09/18/14
20140271645
 Method for treating inflammation patent thumbnailMethod for treating inflammation
A method for treating il-20 induced inflammation. An antagonist to il-20 is administered to treat inflammation and associated diseases.
09/18/14
20140271630
 Rituximab induction therapy followed by glatiramer acetate therapy patent thumbnailRituximab induction therapy followed by glatiramer acetate therapy
The present invention provides a method of treating a subject afflicted with a form of multiple sclerosis or presenting a clinically isolated syndrome comprising periodic administration of an amount of rituximab at least twice to the subject followed by periodic administration of an amount of glatiramer acetate to the subject, wherein the amounts are effective to treat the subject. The present invention also provides a method of treating a subject afflicted with an immune disease, comprising periodic administration of an amount of rituximab at least twice to the subject followed by periodic administration of an amount of glatiramer acetate to the subject wherein the amounts are effective to treat the subject, and wherein the immune disease is an autoimmune disease, an arthritic condition, a demyelinating disease, an inflammatory disease, multiple sclerosis, relapsing-remitting multiple sclerosis, diabetes mellitus, psoriasis, rheumatoid arthritis, inflammatory bowel disease, crohn's disease, or systemic lupus erythematosus..
09/11/14
20140255957
Antigens derived from citrullinated 14-3-3 and uses thereof in the diagnosis of rheumatoid arthritis
The present invention provides citrullinated 14-3-3η peptides and antibodies thereto and methods of using same to evaluate arthritic conditions such as rheumatoid arthritis.. .
09/11/14
20140255422
Antibodies that bind to il-23
The present invention provides an antibody that binds to the p19 subunit of human il-23 and is characterized as having high affinity, selective, and neutralizing properties. The antibody is useful in the treatment or prevention of an autoimmune or inflammatory condition selected from the group consisting of consisting of multiple sclerosis, rheumatoid arthritis, psoriasis, inflammatory bowel diseases, ankylosing spondylitis, graft-versus-host disease, lupus and metabolic syndrome.
09/11/14
20140255406
Anti-tnf-anti-il-17 bispecific antibodies
Bispecific antibodies are provided that specifically bind both tumor necrosis factor alpha (tnfα) and interleukin-17 (il-17). The bispecific antibodies of the invention are useful for treating various autoimmune diseases, including rheumatoid arthritis (ra), psoriatic arthritis (psa), and ankylosing spondylitis (as)..
09/11/14
20140255390
Method of treating rheumatoid arthritis with an anti-il-6r antibody
The present invention provides methods of preventing or treating rheumatoid arthritis using a fully human antibody or antigen-binding fragment thereof that specifically binds human interleukin-6 receptor (hil-6r). The methods of the present invention may include administration of a second therapeutic agent, such as one or more of a non-steroidal anti-inflammatory drug (nsaid), a glucocorticoid, a disease-modifying anti-rheumatic drug (dmard), or a tnf-alpha antagonist, t-cell blocker, anti-cd20 antibody, an il-1, jak or il-17 antagonist, or any combination thereof..
09/11/14
20140255310
Human g protein-coupled receptor and modulators thereof for the treatment of atherosclerosis and atherosclerotic disease and for the treatment of conditions related to mcp-1 expression
The present invention relates to methods of using a g protein-coupled receptor (gpcr) to identify whether a candidate compound is a modulator of atherogenesis. In certain embodiments, the gpcr couples to gi.
09/04/14
20140249130
Bipyridylaminopyridines as syk inhibitors
The present invention provides novel pyrimidine amines of formula i which are potent inhibitors of spleen tyrosine kinase, or are prodrugs thereof, and are useful in the treatment and prevention of diseases mediated by said enzyme, such as asthma, copd and rheumatoid arthritis and cancer.. .
09/04/14
20140248265
Therapeutic antibodies binding il 12rbeta1
The present invention relates to antibodies that specifically bind to il12rβ1, the non-signal transducing chain of the heterodimeric il12 receptor (together with il12rβ2 chain) as well as il23 receptor (together with il23rα chain). The invention more specifically relates to specific antibodies that are il12 and il23 receptor antagonists capable of inhibiting il12/il18 induced ifny production of t cells and compositions and methods of use for said antibodies to treat pathological disorders that can be treated by inhibiting ifny production, such as rheumatoid arthritis, psoriasis or inflammatory bowel diseases or other autoimmune and inflammatory disorders..
08/28/14
20140243382
Inhibitors of c-fms kinase
Wherein z, x, j, r2 and w are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, prostate cancer, lung cancer, colon cancer, stomach cancer, hairy cell leukemia; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, paget's disease, and other diseases in which bone resorption mediates morbidity including rheumatoid arthritis, and other forms of inflammatory arthritis, osteoarthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of formula i, are also provided..
08/28/14
20140243309
Cycloalkylnitrile pyrazole carboxamides as janus kinase inhibitors
The instant invention provides compounds of formula i which are jak inhibitors, and as such are useful for the treatment of jak-mediated diseases such as rheumatoid arthritis, asthma, copd and cancer.. .
08/28/14
20140243301
Chlorobis copper (i) complex compositions and methods of manufacture and use
A method of manufacturing an anhydrous copper complex of formula c12h10cicun2o4 and methods of treating neur-muscular and other diseases, including but not limited to fibromyalgia, multiple sclerosis, muscular dystrophy, rheumatoid arthritis, pain, fatigue, sleeplessness, loss of fine motor control, speech loss, inflexibility, alzheimer's, dementia, amyotrophic lateral sclerosis, depression, lyme disease, lyme disease co-infection, gastroparesis (gp), myopathy, chronic inflammation and/or incontinence. The anhydrous copper complex preferably is administered in a pharmaceutical and/or dietary supplement composition of the invention..
08/28/14
20140243290
Aminopyrimidines as syk inhibitors
The present invention provides novel pyrimidine amines of formula (i) which are potent inhibitors of spleen tyrosine kinase, and are useful in the treatment and prevention of diseases mediated by said enzyme, such as asthma, copd and rheumatoid arthritis.. .
08/28/14
20140243273
Methods for treating inflammatory diseases and pharmaceutical combinations useful therefor
The present invention provides method of treating or lessening the severity of a disease selected from spondyloarthropathy, systemic lupus erythematosus, rheumatoid arthritis, or any combination thereof comprising the administration of a compound of formula i and an optional co-therapy (e.g., chemotherapy agent, dmard, or any combination thereof). The present invention also provides a pharmaceutical composition comprising a compound of formula i, a method of manufacturing a pharmaceutical composition comprising a compound of formula i, and a method of administering a pharmaceutical composition comprising a solid form of a compound of formula i..
08/28/14
20140242170
Corticosteroids for the treatment of joint pain
Corticosteroid microparticle formulations are provided for use for treating pain, including pain caused by inflammatory diseases such as osteoarthritis or rheumatoid arthritis, and for slowing, arresting or reversing structural damage to tissues caused by an inflammatory disease, for example damage to articular and/or peri-articular tissues caused by osteoarthritis or rheumatoid arthritis. Corticosteroid microparticle formulations are administered locally as a sustained release dosage form (with or without an immediate release component) that results in efficacy accompanied by clinically insignificant or no measurable effect on endogenous cortisol production..
08/28/14
20140242073
Cartilage/bone destruction suppressor
An object of the present invention is to provide a cartilage/bone destruction suppressor which can suppress the destruction of cartilage or bone seen in rheumatoid arthritis, osteoarthritis, bone metastasis of malignant tumor, or the like. The present invention relates to a cartilage or bone destruction suppressor comprising an antibody against folate receptor β or a complex of the antibody and a biologically or chemically active substance..
08/21/14
20140235888
(z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluormethylphenyl)-amide tablet formulations with improved stability
The invention relates to solid pharmaceutical compositions comprising (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4′-trifluoromethylphenyl)-amide, as well as a process for the preparation of the same, methods of using such compositions to treat subjects suffering from autoimmune diseases in particular systemic lupus erythematosus or chronic graft-versus-host disease, multiple sclerosis or rheumatoid arthritis.. .
08/21/14
20140235672
Chromene modulators of chemokine receptor activity
Or stereoisomers or prodrugs or pharmaceutically acceptable salts thereof, wherein w1, w2, w3, y, z, r2, r3, r3′ and r4, are defined in the specification. In addition, methods of treating and preventing inflammatory diseases such as asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and transplant rejection using modulators of formula (i) are disclosed..
08/21/14
20140235641
Pyrazole carboxamides as janus kinase inhibitors
The instant invention provides compounds of formula i which are jak inhibitors, and as such are useful for the treatment of jak-mediated diseases such as rheumatoid arthritis, asthma, copd and cancer.. .
08/21/14
20140235543
Methods for isolating and using a subset of cd8 t-cells that are resistant to inhibitors
Methods for identifying a subset of cd8 t cells that is resistant to an inhibitor, specifically cyclosporine, rapamycin and/or tacrolimus, by detecting expression levels of human biomarkers are disclosed. The methods include determining whether a subset of certain cd8 t cells expresses elevated levels of scin and/or pla2g4a, with an elevated level indicative of proliferation of the identified cd8 t cells.
08/21/14
20140234291
Genetic polymorphisms associated with rheumatoid arthritis, methods of detection and uses thereof
The present invention is based on the discovery of genetic polymorphisms that are associated with rheumatoid arthritis. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection..
08/21/14
20140234209
Chimeric and humanized anti-histone antibodies
The present invention concerns chimeric or humanized antibodies or antigen-binding fragments thereof that comprise specific cdr sequences, disclosed herein. Preferably, the antibodies or fragments comprise specific heavy and light chain variable region sequences disclosed herein.
08/14/14
20140228358
Acyclic cyanoethylpyrazoles as janus kinase inhibitors
The instant invention provides compounds of formula i which are jak inhibitors, and as such are useful for the treatment of jak-mediated diseases such as rheumatoid arthritis, asthma, copd and cancer.. .
08/14/14
20140228357
Novel compounds as hif-1alphainhibitors and manufacturing process thereof
The present invention relates to novel compounds as hif-1α inhibitors, manufacturing process thereof, and a pharmaceutical compositions. The compounds according to the present invention having inhibition activity against hif-1α, can be used as a therapeutic prevention and/or treatment for various solid cancers such as colon cancer, liver cancer, stomach cancer and breast cancer.
08/14/14
20140228348
Cyanomethylpyrazole carboxamides as janus kinase inhibitors
The instant invention provides compounds of formula i which are jak inhibitors, and as such are useful for the treatment of jak-mediated diseases such as rheumatoid arthritis, asthma, copd and cancer.. .
08/14/14
20140227711
Genotoxicity as a biomarker for inflammation
The invention provides a method for detection of inflammatory disease in a subject that comprises assaying a test sample of peripheral blood from the subject for a marker of dna damage. An elevated amount of marker present in the test sample compared to control sample is indicative of inflammatory disease activity, including sub-clinical inflammation.
08/14/14
20140227303
Methods for diagnosing and monitoring diseases or conditions using disease modified biomolecules and measurement of a functional immune response
Methods and assays for disease prognosis, detection and treatment monitoring are provided. The assays and methods measure functional immune responses to disease modified biomolecules (dmbs) that are characteristic of a disease of interest.
08/07/14
20140221667
Factor viia inhibitor
The present invention relates to novel inhibitors of factors viia, ixa, xa, xia, in particular factor viia, pharmaceutical compositions comprising these inhibitors, and methods for using these inhibitors for treating or preventing thromboembolic disorders, cancer or rheumatoid arthritis. Processes for preparing these inhibitors are also disclosed..
08/07/14
20140221654
Protease inhibitors
Or a pharmaceutically acceptable salt, n-oxide or hydrate thereof, have utility in the treatment of disorders characterized by inappropriate expression or activation of cathepsin k, such as osteoporosis, osteoarthritis, rheumatoid arthritis or bone metastases.. .
08/07/14
20140221339
Heterocyclic derivative and pharmaceutical drug
Wherein r1 and r2 are the same or different aromatic rings, etc., and ring a is a heterocyclic ring. The compound of the invention or a pharmaceutically acceptable salt thereof has potent mpges-1 inhibiting activity and is useful as an agent for the treatment or prevention of a disease, such as rheumatoid arthritis, osteoarthritis, temporomandibular joint disorders, low back pain, endometriosis, dysmenorrhea, overactive bladder, malignant tumors or neurodegenerative disease..
08/07/14
20140220040
Antibodies to lrp6
Anti-lrp6 antibodies and antigen-binding fragments thereof, as well as pharmaceutical compositions comprising such antibodies and antigen-binding fragments are described. These anti-lrp6 antibodies can be used to enhance wnt activity and/or antagonize dkk1 activity.
07/31/14
20140212429
Binding members-513
This invention relates to binding members, especially antibody molecules, specific for interleukin 1 receptor 1 (il-1r1). For example, isolated binding members specific for il-1r1 which competes with il-1 and il-1ra for binding to il-1r1 and binds il-1r1 with a kd of 10 pm or less when measured by kinexa™.
07/24/14
20140206694
Heterocyclic compounds and their uses
Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (sle), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, the present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110δ activity, including but not restricted to leukemias, such as acute myeloid leukaemia (aml) myelo-dysplastic syndrome (mds) myelo-proliferative diseases (mpd) chronic myeloid leukemia (cml) t-cell acute lymphoblastic leukaemia (t-all) b-cell acute lymphoblastic leukaemia (b-all) non hodgkins lymphoma (nhl) b-cell lymphoma and solid tumors, such as breast cancer.. .
07/24/14
20140206680
Substituted 6-aza-isoindolin-1-one derivatives
Disclosed are compounds of formula 1, and pharmaceutically acceptable salts thereof, wherein g, p, r1, r2, r3a, r4, and r5 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of formula 1, to pharmaceutical compositions which contain them, and to their use for treating disorders, diseases, and conditions involving the immune system and inflammation, including rheumatoid arthritis, cancer, and other disorders, diseases, and conditions for which inhibition of syk is indicated..
07/17/14
20140200635
Phototherapy device
Provided is a phototherapy device which enables a sufficient amount of light to reach a deep tissue to achieve a satisfactory therapy while preventing the increase in the skin temperature of an affected part, and which can achieve a comfortable therapy. The present invention provides a phototherapy device comprising a sheet-like member having a first surface on which an affected part is to be arranged and a surface light source for emitting light toward the sheet-like member, wherein the first surface is formed in an uneven shape so as to provide multiple grooves.
07/17/14
20140200260
Methods for determining and inhibiting rheumatoid arthritis associated with the braf oncogene in a subject
The invention provides methods for determining whether a subject is suffering from a rheumatoid arthritis associated with the braf oncogene comprising contacting isolated fibroblasts from the subject with a molecule or pool of molecules directed to the braf oncogene; and culturing the sample in the presence of the agent and determining whether braf oncogene expression by the cell is decreased and/or whether cells in the sample return to a less transformed phenotype, exhibit decreased cell proliferation and/or exhibit increased contact inhibition, any of which is indicative that the subject is suffering from a rheumatoid arthritis associated with the braf oncogene.. .
07/17/14
20140200245
Inhibitors of c-fms kinase
Wherein z, x, j, r2 and w are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, prostate cancer, lung cancer, colon cancer, stomach cancer, hairy cell leukemia; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, paget's disease, and other diseases in which bone resorption mediates morbidity including rheumatoid arthritis, and other forms of inflammatory arthritis, osteoarthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of formula i, are also provided..
07/17/14
20140199414
Krill and/or marine extracts for prevention and/or treatment of cardiovascular diseases, arthritis, skin cancer, diabetes, premenstrual syndrome and transdermal transport
The present invention relates to a method of treatment and/or prevention of cardiovascular disease, rheumatoid arthritis, skin cancer, premenstrual syndrome, diabetes and transdermal transport enhancement. The method comprises the administration of a therapeutically effective amount of krill and/or marine oil to a patient.
07/10/14
20140194413
Inhibitors of bruton's tyrosine kinase
Wherein, variables r, x, y1, y2, y2′, y3, y4, n and m are defined as described herein, which inhibit btk. The compounds disclosed herein are useful to modulate the activity of btk and treat diseases associated with excessive btk activity.
07/10/14
20140194343
Ctrp6 which can be used as therapeutic and prophylactic agent for autoimmune diseases
[solution] a pharmaceutical composition containing ctrp6 for the prevention or treatment of autoimmune disease. Ideally, a pharmaceutical composition for the prevention or treatment of inflammation associated with autoimmune disease, for example, rheumatoid arthritis or type 1 diabetes, is provided..
07/10/14
20140194308
Use of myelin basic protein as a novel genetic factor for rheumatoid arthritis
A method of testing for rheumatoid arthritis, comprising detecting an autoantibody to myelin basic protein in a biological sample from a subject. A test kit for rheumatoid arthritis, comprising myelin basic protein.
07/10/14
20140193411
Multimeric constructs
Multimeric fusion proteins of an ig-like domain of flt-1 are rendered functional by inclusion of a linker moiety. Vectors encoding the fusion proteins and host cells expressing the fusion proteins can be used therapeutically to block neovascularization in individuals with pathological conditions related to neovascularization.
07/10/14
20140193366
Modulators of mir-323-3p for the prevention or treatment of rheumatoid arthritis
A mir-323-3p inhibitor is provided for the prevention or therapy of rheumatoid arthritis, comprising a sequence capable of forming a hybrid to mir-323-3p as an oligonucleotide or a vector from which such oligonucleotide is transcribed, or as a mirna decoy or sponge.. .
06/26/14
20140179750
Prostaglandin receptor ep2 antagonists, derivatives, compositions, and uses related thereto
The disclosure relates to prostaglandin receptor ep2 antagonists, derivatives, compositions, and methods related thereto. In certain embodiments, the disclosure relates to methods of treating or preventing conditions and diseases in which ep2 receptor activation has a physiological role, such as but not limited to, brain injury, inflammatory diseases, neuroinflammation after a seizure, pain, endometriosis, cancer, rheumatoid arthritis, skin inflammation, vascular inflammation, colitis, and neurological disorders by administering a pharmaceutical composition comprising a compound disclosed herein to a subject in need thereof..
06/26/14
20140178509
Formulation of a mixture of free-b-ring flavonoids and flavans as a therapeutic agent
The present invention provides a novel composition of matter comprised of a mixture of two specific classes of compounds—free-b-ring flavonoids and flavans—for use in the prevention and treatment of diseases and conditions mediated by the cox-2 and 5-lo pathways. The present invention further provides a novel method for simultaneously inhibiting the cyclooxygenase-2 (cox-2) and 5-lipoxygenase (5-lo) enzymes, and reducing cox-2 mrna production.
06/26/14
20140178389
Il-1 binding proteins
The disclosure provides binding proteins that specifically bind to il-1α and il-1β. These binding proteins can be organized into dvd-igs.
06/19/14
20140171469
Pyrazolyl substituted carbonic acid derivatives as modulators of the prostacyclin (pgi2) receptor useful for the treatment of disorders related thereto
Pyrazole derivatives of formula ia and pharmaceutical compositions thereof that modulate the activity of the pgi2 receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of: pulmonary arterial hypertension (pah) and related disorders; platelet aggregation; coronary artery disease; myocardial infarction; transient ischemic attack; angina; stroke; ischemia-reperfusion injury; restenosis; atrial fibrillation; blood clot formation in an angioplasty or coronary bypass surgery individual or in an individual suffering from atrial fibrillation; atherosclerosis; atherothrombosis; asthma or a symptom thereof; a diabetic-related disorder such as diabetic peripheral neuropathy, diabetic nephropathy or diabetic retinopathy; glaucoma or other disease of the eye with abnormal intraocular pressure; hypertension; inflammation; psoriasis; psoriatic arthritis; rheumatoid arthritis; crohn's disease; transplant rejection; multiple sclerosis; systemic lupus erythematosus (sle); ulcerative colitis; ischemia-reperfusion injury; restenosis; atherosclerosis; acne; type 1 diabetes; type 2 diabetes; sepsis; and chronic obstructive pulmonary disorder (copd)..
06/19/14
20140171437
Oxazole derivatives useful as inhibitors of faah
The present invention is directed to certain oxazole derivatives which are useful as inhibitors of fatty acid amide hydrolase (faah). The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and their formulations in the treatment of certain disorders, including osteoarthritis, rheumatoid arthritis, diabetic neuropathy, postherpetic neuralgia, skeletomuscular pain, and fibromyalgia, as well as acute pain, migraine, sleep disorder, alzeimer disease, and parkinson's disease..
06/19/14
20140170683
Citrullinated peptides for diagnosing and prognosing rheumatoid arthritis
The present invention provides novel citrullinated peptides, their use in methods for aiding, assisting, improving, or facilitating the diagnosis or prognosis of rheumatic diseases such as rheumatoid arthritis (ra), and methods for identifying novel citrullinated peptides that are immunoreactive with anti-citrullinated protein antibodies (acpas). The present invention also provides methods for detecting rheumatoid factor (rf) using novel rf detection reagents as a means to aid, assist, improve, or facilitate the diagnosis or prognosis of rheumatic diseases such as ra.
06/12/14
20140162983
Compositions and methods for the production of pyrimidine and pyridine compounds with btk inhibitory activity
The present invention provides novel pyrimidine and pyridine compounds according to formula (i), formula (ii), formula (iii), formula (iv) and formula (v) their manufacture and use for the treatment of hyperproliferative diseases including, but not limited to, cancer, lupus, allergic disorders, sjogren's disease and rheumatoid arthritis. In preferred embodiments, the present invention describes irreversible kinase inhibitors including, but not limited to, inhibitors of bruton's tyrosine kinase..
06/05/14
20140155461
Molecular targets and compounds, and methods to identify the same, useful in the treatment of bone and joint degenerative diseases
The present invention relates to methods for identifying agents capable of inhibiting the expression or activity of proteins involved in the processes modulating osteoclastogenesis, which inhibition is useful in the prevention and/or treatment of bone and joint degenerative diseases and diseases involving aberrant activity or differentiation of osteoclasts. In particular, the present invention provides methods for identifying agents for use in the prevention and/or treatment of rheumatoid arthritis..
06/05/14
20140155377
3-cycloalkylaminopyrrolidine derivatives as modulators of chemokine receptors
(wherein r1, r2, r3, r4, r5, r6, r7, y and z are as defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of chemokine receptors and more specifically as modulators of the ccr2 and/or ccr5 receptor.
06/05/14
20140154247
Biological markers and methods for predicting response to b-cell antagonists
Biological markers that predict patient responsiveness to b-cell antagonists are provided. Also provided are methods of using such biological markers.
05/29/14
20140148474
Aminopyrimidines as syk inhibitors
The present invention provides novel pyrimidine amines of formula i which are potent inhibitors of spleen tyrosine kinase, and are useful in the treatment and prevention of diseases mediated by said enzyme, such as asthma, copd, rheumatoid arthritis and cancer.. .
05/29/14
20140148459
Matrix metalloproteinase inhibitors
This invention also relates to pharmacological compositions containing the compounds of the present invention, and methods of treating asthma, rheumatoid arthritis, copd, rhinitis, osteoarthritis, psoriatic arthritis, psoriasis, pulmonary fibrosis, pulmonary inflammation, acute respiratory distress syndrome, periodontitis, multiple sclerosis, gingivitis, gingivitis, atherosclerosis, dry eye, neointimal proliferation, which leads to restenosis and ischemic heart failure, stroke, renal diseases, tumor metastasis, and pounds.. .
05/29/14
20140148405
Composition and method to alleviate joint pain using a mixture of fish oil and fish oil derived, choline based, phospholipid bound fatty acid mixture including polyunsaturated epa and dha
Beneficial and synergistic effects for alleviating joint pain and symptoms of osteoarthritis and/or rheumatoid arthritis have been found using a mixture of fish oil and fish oil derived, choline based, phospholipid bound fatty acid mixture including polyunsaturated epa and dha either alone or in combination with other active constituents, including astaxanthin and polymeric hyaluronic acid or sodium hyaluronate (hyaluronan) in an oral dosage form.. .
05/29/14
20140147453
Fusion peptide comprising dhfas-1 domain and mmp substrate and use thereof for preventing and treating rheumatoid arthritis
The present invention relates to a fusion peptide comprising dhfas-1 domain and mmp substrate and use thereof. More specifically, the present invention relates to a fusion peptide, comprising a) a dhfas-1 domain which is the fourth fas-1 domain of βig-h3 lacking h1 and h2 regions; b) a mmp (matrix metalloproteinase) substrate; and c) a peptide comprising rgd motif and an use thereof for preventing and treating inflammatory disease.
05/22/14
20140142135
4-dimethylamino-phenyl-substituted naphthyridines, and use thereof as medicaments
R1 and r6 may have the meanings as described in claim 1, as well as medicaments which contain these compounds. Further, the invention relates to methods of treating a disease selected from asthma, copd, allergic rhinitis, adult respiratory distress syndrome, bronchitis, allergic dermatitis, contact dermatitis, idiopathic thrombocytopenic purpura, rheumatoid arthritis and allergic rhinoconjunctivitis by administrating an appropriate amount of a compound of formula 1 to a patient in need thereof..
05/22/14
20140142109
Antifolate combinations
The present invention provides combinations of active agents, such combinations comprising one or more antifolate compounds. The particularly can include methotrexate and one or more further antifolate compounds.
05/22/14
20140142100
New macrolides and their use
The use of said compounds as medicaments, in particular for the treatment or prevention of inflammatory and allergic diseases, pharmaceutical compositions containing said compounds and to processes for their preparation. The invention relates in particular to macrolide compounds with antiinflammatory activity mediated primarily through inhibition of phosphodiesterase 4 (pde4) which makes them useful for the treatment and/or prevention of inflammatory and allergic diseases such as chronic obstructive pulmonary disease (copd), asthma, rheumatoid arthritis, atopic dermatitis or inflammatory bowel disease or proliferative diseases such as cancer..
05/22/14
20140141077
Composition for use in treating and preventing inflammation related disorder
The present invention is related to a use for treating and preventing inflammation related disorder of a composition containing a drug and hyaluronic acid (ha) or ha mixture, whereas the ha or the ha mixture as a delivery vehicle can be a formulation including at least two has having different average molecular weights. The composition has been demonstrated to be capable of reducing the therapeutic dose of a drug on the treatment and prevention of inflammation related disorders is acute inflammatory disease, chronic obstructed pulmonary disease, coeliac disease, conjunctivitis, otitis, allergic rhinitis, gingivitis, aphthous ulcer, bronchitis, gastroesophageal reflux disease (gerd), esophagitis, gastritis, enteritis, peptic ulcer, inflammatory bowel disease (ibd), crohn's disease, irritable bowel syndrome (ibs), intestinal inflammation or allergy, urethritis, cystitis, vaginitis, proctitis, eosinophilic gastroenteritis, or rheumatoid arthritis..
05/22/14
20140141018
Antagonist anti-il-7 receptor antibodies and methods
The present invention provides antagonizing antibodies that bind to interleukin-7 receptor (il-7r). The invention further provides a method of obtaining such antibodies and antibody-encoding nucleic acids.


Popular terms: [SEARCH]

Rheumatoid Arthritis topics: Rheumatoid Arthritis, Osteoarthritis, Autoimmune, Multiple Sclerosis, Immune Disease, Autoimmune Disease, Antibodies, Astaxanthin, Hyaluronate, Hyaluronic Acid, Joint Pain, Hyaluronan, Immune Diseases, Autoimmune Diseases, Lung Cancer

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Rheumatoid Arthritis for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Rheumatoid Arthritis with additional patents listed. Browse our RSS directory or Search for other possible listings.
     SHARE
  
         


FreshNews promo



0.3619

3973

0 - 1 - 71